- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Parity Laws and the Need for Payment Reform
During this segment, Scott Gottlieb, MD; Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, continue the discussion regarding issues that affect new oncology care models, including drug wastage, patient compliance, and treatment costs.
As more oncology drugs are being dispensed via practice-based pharmacies, intervention is needed to reduce waste, Dr Kolodziej comments. Also, compliance remains an issue even with the advent of practice-based pharmacies.
Although some states have passed parity laws, meaning that patient out-of-pocket (OOP) costs for oral medications should not be greater than OOP costs for intravenous medications, high OOP costs remain a barrier to patient access to treatment.
Dr Kiss discusses the buy-and-bill model’s impact on oncology and suggests that payment reform is necessary. Oncologists should be compensated for providing cognitive and technical services, he believes, rather than for dispensing chemotherapy drugs.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
